يعرض 1 - 10 نتائج من 143 نتيجة بحث عن '"Cd38 expression"', وقت الاستعلام: 1.00s تنقيح النتائج
  1. 1
    دورية أكاديمية

    وصف الملف: application/pdf

  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    رسالة جامعية
  5. 5
    رسالة جامعية
  6. 6
    دورية أكاديمية

    المصدر: Frerichs , K A , Minnema , M C , Levin , M D , Broijl , A , Bos , G M J , Kersten , M J , Mutis , T , Verkleij , C P M , Nijhof , I S , Maas-Bosman , P W C , Klein , S K , Zweegman , S , Sonneveld , P & van de Donk , N W C J 2021 , ' Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma ' , Blood advances , vol. 5 , no. 23 ....

  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9

    المساهمون: Hematology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), Internal medicine, Hematology laboratory, Anatomy and neurosciences, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology

    المصدر: Verkleij, C P M, Frerichs, K A, Broekmans, M E C, Duetz, C, O'Neill, C A, Bruins, W S C, Homan-Weert, P M, Minnema, M C, Levin, M-D, Broijl, A, Bos, G M J, Kersten, M J, Klein, S K, Shikhagaie, M M, Casneuf, T, Abraham, Y, Smets, T, Vanhoof, G, Cortes-Selva, D, van Steenbergen, L, Ramos, E, Verona, R I, Krevvata, M, Sonneveld, P, Zweegman, S, Mutis, T & van de Donk, N W C J 2023, ' NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma ', HemaSphere, vol. 7, no. 5, pp. E881 . https://doi.org/10.1097/HS9.0000000000000881Test
    HemaSphere, 7(5):E881. Wolters Kluwer Health
    HemaSphere, 7(5):e881. Wolters Kluwer Health
    HemaSphere, 7(5). Wolters Kluwer Health

    وصف الملف: application/pdf

  10. 10

    المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), Institut Català de la Salut, [Carlo-Stella C] Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milano, Italy. [Zinzani PL] IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia 'Seràgnoli' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy. [Sureda A] Institut Català D'Oncologia ‐ Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain. [Araújo L] Universitário de Coimbra, Coimbra, Portugal. [Casasnovas O] Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France. [Carpio C] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Hematology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology

    المصدر: Hematological Oncology, 41(1), 108-119. Wiley
    Scientia
    Carlo-Stella, C, Zinzani, P L, Sureda, A, Araújo, L, Casasnovas, O, Carpio, C, Yeh, S-P, Bouabdallah, K, Cartron, G, Kim, W S, Cordoba, R, Koh, Y, Re, A, Alves, D, Chamuleau, M, le Gouill, S, López-Guillermo, A, Moreira, I, van der Poel, M W M, Abbadessa, G, Meng, R, Ji, R, Lépine, L, Saleem, R & Ribrag, V 2022, ' A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma ', Hematological Oncology . https://doi.org/10.1002/hon.3089Test
    Hematological Oncology. John Wiley and Sons Ltd

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, BONE-MARROW, Immunology, diffuse large B-cell lymphoma, Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized [CHEMICALS AND DRUGS], Biochemistry, Gastroenterology, BRENTUXIMAB VEDOTIN, HODGKIN-LYMPHOMA, Hodgkin, Malaltia de - Tractament, Internal medicine, Phase (matter), MULTIPLE-MYELOMA, Medicine, Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, T-Cell::Lymphoma, T-Cell, Peripheral [DISEASES], aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados [COMPUESTOS QUÍMICOS Y DROGAS], In patient, Other subheadings::/therapeutic use [Other subheadings], peripheral T-cell lymphoma, CELL LYMPHOMA, Isatuximab, neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células T::linfoma de células T periféricas [ENFERMEDADES], Anticossos monoclonals - Ús terapèutic, Otros calificadores::/uso terapéutico [Otros calificadores], business.industry, non-Hodgkin lymphoma, NIVOLUMAB, SAR650984, General Medicine, Cell Biology, Hematology, medicine.disease, neoplasias::neoplasias por tipo histológico::linfoma::enfermedad de Hodgkin [ENFERMEDADES], Lymphoma, CD38 EXPRESSION, Oncology, Multicenter study, Limfomes - Tractament, cemiplimab, Open label, business, Neoplasms::Neoplasms by Histologic Type::Lymphoma::Hodgkin Disease [DISEASES], isatuximab

    وصف الملف: application/pdf